


- Sweeney C, Martin AJ, Zielinski RR, Thomson A, Tan TH, Sandhu SK, Reaume MN,


EORTC-NCI-AACR SYMPOSIUM. 2018.


2017


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

Lymphoma (RR-DLBCL) - Outcome of Ibrutinib+R-GDP. Hematological Oncology 35, 88. 2017.


Comparison of Outcomes By Age of Patients with Limited Stage Hodgkin Lymphoma Treated with ABVD Alone; A Secondary Analysis of the Canadian Cancer Trial Group HD.6 Trial. Blood 130: 4081, 2017.


- Wells C, Siu LL, Shapiro JD, Tu D, Jonker DJ, Karapelis CS, Simes J, Liu G, Price TJ, Tebbutt NC, O’Callaghan CJ. Age as a predictive and prognostic factor for targeted therapy treatment in metastatic chemoresistant colorectal cancer (CRC): An analysis of
2016


2015


• Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[ supp]; abstr e17710.

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

- Penniment MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[(suppl 3; abstr 6)]. 2015.


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


- Kangarloo SB, Ng ESM, Bramwell VHC, Pritchard KI, Shepherd LE, Tu D, Magliocco AM, Tang PA. Pharmacokinetic analysis of tamoxifen metabolites in premenopausal...


phase III trial comparing immediate versus deferred chemotherapy after radical
cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the

- Tang PA, Hay AE, O'Callaghan CJ, Mittmann N, Chambers C, Pater JL, Leiplh NB.
Estimation of drug cost avoidance (DCA) and pathology cost avoidance (PCA) through
participation in NCIC clinical trials group (NCIC-CTG) phase III clinical trials in Canada. J
Clin Oncol 32:5s[suppl; abstr 6560]. 2014.

Shepherd LE, Gelmon KA, Lohrisch CA. Outcomes of 3-weekly doxorubicin and
cyclophosphamide followed by Paclitaxel (AC/T) in a randomized trial (RCT), compared
to a case-control matched British Columbia (BC) breast cancer population. J Clin Oncol
32:5s[suppl; abstr 1037]. 2014.

- Wong R, Au H-J, Ding K, Harvey JA, Stephens S, O'Callaghan CJ, Kneebone A, Ngan
in patients with malignant dysphagia: An international randomized trial comparing
radiotherapy alone (RT) versus chemoradiotherapy (CRT)—TROG03.01 NCICCTG ES2.

- Bar J, Ding K, Zhao H, Laurie SA, Han L, Shepherd FA, Addison CL, Goss GD,
Dimitroulakos J, Bradbury PA. Exploratory analysis of angiotensin converting enzyme
(ACE) and aldosterone (Ald) serum levels as prognostic and predictive biomarkers on
the NCIC CTG BR24 trial. J Clin Oncol 31[suppl; abstr 8048], 2013.

- Baumert BG, Mason WP, Ryan G, Bromberg JE, van den Bent MJ, Hoang-Xuan K,
Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Rees J, Wick W, Von Deimling A,
Hartmann C, Kros JM, Hegi ME, Dif N, Lacombe DA, Gorlia T, Stupp R. Temozolomide
chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade
glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-

- Booth CM, Courneya KS, Vardy JL, Jonker DJ, Gill S, Brundage M, van der Ploeg H,
RM. A phase III study of the impact of a physical activity program on disease-free
survival in patients with high-risk stage II or stage III colon cancer: A randomized
controlled trial (NCIC CTG CO.21). J Clin Oncol 31[suppl; abstr TPS3647], 2013.

- Brule SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC,
Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA. Location of colon cancer (right-
sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC

- Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK,
Rinn K, Albain KS, Chew HK, Von Burton G, Moore TD, Srkalovic G, McGregor BA,
Flaherty LE, Livingston RB, Lew D, Gralow J, Hortobagyi G. S0221: Comparison of two
schedules of paclitaxel as adjuvant therapy for breast cancer. J Clin Oncol 31[suppl;
abstr CRA1008], 2013.


SD, Chalchal HI, Oja CD, Tonkin KS, Bernstein V, Chen BE, Stambolic V. Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC). J Clin Oncol 31[suppl; abstr 1033], 2013.


- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[suppl; abstr 6557], 2013.


- Raja FA, Perren TJ, Embleton A, Rustin GJS, Jayson G, Swart AM, Vaughan M, Hirte H,

- Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[suppl; abstr 4061], 2013.

2012

- Chapman J-AW, Costantino JP, Dong B, Margolese RG, Pritchard KI, Shepherd LE, Gelmon KA, Wolmark N, Pollak MN. Randomized trials of adjuvant tamoxiften versus


- Eisenhauer EA. Antiangiogenics in ovarian cancer: where are we now? Ann Oncol 23[suppl 9, abstr 54In], ix40-ix41, 2012.


Leighl NB, Tsao MS, Ho C, Shepherd FA, Murray N, Goffin J, Nicholas G, Seymour L, Goss GD, Bradbury P. NCIC CTG IND.196: Phase I Study of Foretinib (GSK1363089) and Erlotinib in Patients with Advanced Pretreated NSCLC. EORTC-NCI-AACR Symposium [abstr 607], 2012.

Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[ suppl, abstr 524], 2012.


- Steele R, Quirke P, Grieve R, Monson J, Couture J, de Metz C, Pugh C, Nichols L, Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term
Outcome After Anastomotic Leak and the Impact of Short Course Pre-Operative Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European Multidisciplinary Colorectal Cancer Congress, 2012.


2011


analysis of the impact of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy (ACT) in node negative (N0) non-small cell lung cancer (NSCLC). J Thoracic Oncol 6[6 suppl 2, abstr O42.01], S462, 2011.


- Goss PE, Ingle JN, Alés-Martinez J, Cheung A, Chlebowski RT, Wactawski-Wende J,


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


• Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


• Mehta RS, Barlow WE, Albain KS, Vandenberg T, Dakhil SR, Tirumali NR, Lew DL,


- Scott DW, Chan FC, Hong F, Rogic S, Tan K, Meissner B, Farinha P, Horning SJ, Fisher


2010

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.


- Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


- Lee CK, Guardiola E, Hogberg T, Friedlander M, Bentley J, Denison U, Vergote IB,


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

28[15s, abstr 1578], 2010.


2009


S288. 2009.


- Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.


- Eisenhauer EA, Verweij J. New response evaluation criteria in solid tumors: RECIST


• Palmer M, Broxterman J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It's a snap! Clinical Trials 6, 536, 2009.


2008


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

- Laurie SA, Arnold A, Shepherd FA, Dediu M, Ciuleanu T, Fenton D, Zukiw M, Goss G, Ding K, Seymour L. Randomized double-blind phase II trial of carboplatin + paclitaxel with either daily oral cediranib, an inhibitor of vascular endothelial growth factor receptor


Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


• Zhu L, Tan X, Tu D. Testing the homogeneity of two survival functions against a mixture alternative based on censored data. Statistical Society of Canada, 2008.

2007


- Catton C, Saad F, Sydes M, Parulekar W, Savage C, Kynaston H, Logue J, Murphy C,


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.

**2006**


• Fuchs C, Tepper JE, Niedzwiecki D, Hollis D, Haller DG, Dragovich T, Alberts SR, Bjarnason G, Mayer RJ. Postoperative adjuvant chemoradiation for gastric or gastroesophageal adenocarcinoma using epirubicin, cisplatin, and infusional 5-FU
before and after CI 5-FU and radiotherapy: Interim toxicity results from Intergroup trial CALGB 80101. ASCO Gastrointestinal Cancers Symposium [Abstr 61], 2006.


O’Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis I, Pritchard KI. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1], S18, 2006.


Sebag-Montefiore D, Steele R, Quirke P, Grieve R, Khanna S, Monson J, Holliday A,


2005


<table>
<thead>
<tr>
<th>Authors</th>
<th>Title</th>
<th>Journal and Volume</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laurie SA, Arnold A, Gauthier I, Ellis P, Goss G, Chen E, Shepherd F, Fisher B,</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.

Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.


Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.


Paul N, Wong R, Brundage M, Ding K, Whitehead M, Pater J. Symptom assessment in


- Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.


• Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.


<table>
<thead>
<tr>
<th>Authors</th>
<th>Title</th>
<th>Journal/Conference</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sloan JA, McLeod H, Sargent D, Zhao X, Fuchs C, Ramanathan RK, Williamson S,</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2003

• Li D. A SAS macro to automate the covariance structure determination in repeated measures data analysis with mixed procedure. Pharmaceutical Industry SAS Users Group, 2003.
• Mazumdar M, Tu D. Efficiency of STRTA matched case-control studies with multiple controls per case in survival data setting. Controlled Clin Trials 24(3S), 112S, 2003.


2002


• Rothenberg M, Liu PY, Wilczynski S, Braly PS, Wadler S, Stuart G, Hannigan EV, Bonebrake AJ, Alberts DS, Markman M. Excellent 2-year survival in women with


2001


- Moore M, Chi K, Ernst S, Belanger K, Tannock I, Bjarnason G, Stewart D, Goel R,


2000


Eisenhauer E, Gelmon K, Hirte H, Fisher B, Walsh W, Ptaszynski M, Onetto N, Zee B. Predictors of inter-patient toxicity in a phase I trial of NX211 given in a daily x 3


• Stewart D, Donehower RC, Eisenhauer E, Wainman N, Moore M, Bonfilis C, Reid G. A phase I and pharmacokinetic study of MG98, a human DNA methyltransferase
(MeTasse) antisense oligonucleotide, given as a 2-hour twice weekly infusion 3 out of every 4 weeks. Clinical Cancer Research 6(Suppl), 4571, 2000.


1999


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


1998

- Gelmon K, Tomiak E, Tolcher A, Blackstein M, Zee B, Batist G, Iglesias J, Fisher B,


- Moore M, Tannock I, Winquist E, Tolcher A, Bennett K, Seymour L. Gemcitabine and

- Tu D, Zee B, Pater J. Duration projection for equivalence clinical trials with survival


1997


- Dancey J, Zee B, Whitehead M, Palmer M, Osoba D, Pater J. Gender and age influence


- Shepherd L, Findlay B, Tonkin K, Crump M, Norris B, Trudeau M, Blackstein M, Burnell...


- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.


1995


- Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.
- Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.
- Palmer M, Zee B, Osoba D, Pater J, Lofters W, Chin C, Dempsey E. Day of assessment


1994


Shepherd F, Eisenhauer E, Latreille J, Fisher B, Hellmann S. Phase I trial of paclitaxel


1993


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

- Paul N. The success of clinical trials depends on good communication. Joint meeting of EORTC SGDM and BODMA, 1993.


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


- Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.


Pater J, Smaldone L, Zee B, Goodlow J, Rusthoven J, Rozencweig M. Simultaneous randomization to multiple dose levels and an active comparator as a means of


1990


Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.


1988


1986

- Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.
1985


1984


1983


1981

